ArticleAngewandte Chemie (International ed. in English)2026
Water-Dispersible Ruthenium Nanocatalyst for Carbonyl Reduction With D
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The growing development of biologics as therapeutic agents urges the development of efficient catalytic methods enabling the direct incorporation of hydrogen isotopes from readily available and easy-to-handle isotopic sources in aqueous media. In this context, we report the synthesis and characterization of water-dispersible ruthenium nanoparticles stabilized by the commercially available phosphine ligand sSPhos, and their application as catalysts for carbonyl reduction reactions under low-pressure deuterium and tritium atmospheres. Using this nanocatalyst, a broad range of functionalized deuterated alcohols was successfully obtained in high isotopic enrichment from diverse aldehyde precursors, including a large cyclic peptide derivative (acetyl-cyclosporin A). Mechanistic investigations revealed that in some cases, deuterium incorporation proceeds through both hydrogen isotope exchange on the aldehyde starting material and the reductive deuteration pathway. To demonstrate the synthetic utility of this methodology for the regioselective labeling of complex molecules, a two-step sequence consisting of Bobbitt's salt-mediated oxidation of the alcohol followed by its reductive deuteration was successfully applied to the active pharmaceutical ingredient losartan and a peptide-derived cathepsin-cleavable linker widely used in antibody-drug conjugates. Together with the successful tritiation experiment, these results highlight the broad method potential for the challenging hydrogen isotope labeling of complex polar molecules and biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.